VANCOUVER, BC, August 22, 2023 — WEX Pharmaceuticals Inc. (“WEX”, or the “Company”), a biopharmaceutical company based in Vancouver, Canada developing a non-opioid analgesic, Halneuron® (“tetrodotoxin” or “TTX”), today announced the publication of a recent patent application filed with the World the Intellectual Property Organization (WIPO) through the Patent Cooperation Treaty (“PCT”). The application, as published is directed to a novel injectable formulation of tetrodotoxin.